siRNA-Loaded Hydroxyapatite Nanoparticles for <i>KRAS</i> Gene Silencing in Anti-Pancreatic Cancer Therapy.

Pharmaceutics · 2021 · PMC8466089 · PMID 34575504

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As listed in Table 2 , the decrease of Kras protein expression level in both PANC-1 and CFPAC-1 cells showed a trend with siRNA-mate/siKras > HAp-PEI/siKras > HAp/siKras, while other treatments, including free siKras, did not display significant influences, which is also consistent with the downregulation expression of Kras mRNA as shown in Figure 7 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.